The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.
Ann Oncol
; 24(3): 618-24, 2013 Mar.
Article
de En
| MEDLINE
| ID: mdl-23136233
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs du sein
/
Antinéoplasiques hormonaux
/
Récidive tumorale locale
Type d'étude:
Etiology_studies
/
Guideline
/
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Qualitative_research
/
Risk_factors_studies
Limites:
Female
/
Humans
/
Middle aged
Langue:
En
Journal:
Ann Oncol
Sujet du journal:
NEOPLASIAS
Année:
2013
Type de document:
Article
Pays de publication:
Royaume-Uni